Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
stocknews21h
3 Biotech Stocks Innovating the Future of Medicine
The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...
Truist Financial Sticks to Their Buy Rating for Biogen (BIIB)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...
Biogen price target lowered to $220 from $302 at Truist
Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...
Solid Biosciences stock jumps 11% post-market on FDA update
Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects ...
Biogen price target lowered to $231 from $260 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $231 from $260 and keeps an Outperform rating on the shares as part of a ...
Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, fell about 0.9% ...
Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold
Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
In order from steepest decline to narrowest, the five unloved were Intel(NASDAQ: INTC), MongoDB(NASDAQ: MDB), Biogen(NASDAQ: BIIB), DexCom(NASDAQ: DXCM), and Microchip Technology(NASDAQ: MCHP).